Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 6/20 | 0.47 |
| ▸ | METAP1 | P53582 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690082 | 1.00 | REN (0.47) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL7151431 | 1.00 | REN (0.47) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL7298627 | 0.91 | ANPEP (0.44) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL10659068 | 0.85 | ALDH1A1 (0.46) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL7275103 | 0.85 | ALDH1A1 (0.46) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL9502249 | 0.85 | ALDH1A1 (0.46) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL7268624 | 0.83 | METAP1 (0.47) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL10433763 | 0.83 | REN (0.45) | RENMETAP2METAP1SLC1A3SLC1A2 | |
| SCHEMBL7330492 | 0.83 | METAP1 (0.47) | RENMETAP2METAP1ALDH1A1ALOX5 | |
| SCHEMBL7284456 | 0.81 | REN (0.44) | RENMETAP2METAP1ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518080-B1 | Antibiotic peptides | AMP THERAPEUTICS GMBH (DE) | 2016-05-18 | — | — | EP | claimed |
| US-20150315241-A1 | Antibiotic Peptides | AMP-THERAPEUTICS GMBH (DE) | 2015-11-05 | — | — | US | claimed |
| US-9060513-B2 | Antibiotic peptides | AMP-THERAPEUTICS GMBH (DE) | 2015-06-23 | — | — | US | claimed |
| US-20140057850-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | ORGANOBALANCE GMBH (DE) | 2014-02-27 | — | — | US | claimed |
| EP-2673288-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | Organo Balance GmbH (DE) | 2013-12-18 | — | — | EP | claimed |
| EP-2170928-B1 | ANTIBIOTIC PEPTIDES | AMP THERAPEUTICS GMBH (DE) | 2013-07-03 | — | — | EP | claimed |
| EP-2518080-A2 | Antibiotic peptides | AMP-Therapeutics GmbH & Co. KG (DE) | 2012-10-31 | — | — | EP | claimed |
| WO-2012107244-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | ORGANOBALANCE GMBH (DE) | 2012-08-16 | — | — | WO | claimed |
| US-20100222268-A1 | ANTIBIOTIC PEPTIDES | AMP-THERAPEUTICS GMBH & CO. KG | 2010-09-02 | — | — | US | claimed |
| CN-101801995-A | Antibacterial peptide | AMP THERAPEUTICS GMBH & CO KG | 2010-08-11 | — | — | CN | claimed |
| EP-2170928-A1 | ANTIBIOTIC PEPTIDES | AMP-Therapeutics GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009013262-A1 | ANTIBIOTIC PEPTIDES | UNIVERSITÄT LEIPZIG (DE) | 2009-01-29 | — | — | WO | claimed |
| EP-0211744-B1 | PEPTIDIC AMINO-ALCOHOL DERIVATIVES CONTAINING A TETRA-SUBSTITUTED CARBON ATOM, INHIBITORS OF RENIN AND OF ACID PROTEASES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS | SANOFI (FR) | 1991-12-04 | — | — | EP | claimed |
| EP-0416740-A2 | Novel compounds with renin-inhibiting activity | Beecham Group p.l.c. (GB) | 1991-03-13 | — | — | EP | claimed |
| EP-0411751-A1 | Renin inhibitory peptides | Beecham Group p.l.c. (GB) | 1991-02-06 | — | — | EP | claimed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | claimed |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12595260-B2 | Stable heavy isotopes in amide functional groups and uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-0222283-A2 | Amino-acid derivatives | MERCK PATENT GmbH (DE) | 1987-05-20 | — | — | EP | disclosed |
| EP-0220665-A2 | Peptides | MERCK PATENT GmbH (DE) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057850-A1 | PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS | NGLY1, FPR3, CUTA | REN 269/4885METAP2 236/4885METAP1 97/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | REN 1940/4885METAP2 1368/4885METAP1 906/4885 |
| US-12595260-B2 | Stable heavy isotopes in amide functional groups and uses thereof | SLC10A1, SLC9A1, SLC10A6 | REN 206/4885METAP2 2230/4885METAP1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.